Research suggests new approaches to treat AD Research aimed at understanding the host-microbial interface in atopic dermatitis is ongoing but already providing insights for novel therapeutic strategies. FDA approves corticosteroid-sparing topical option for eczema January 17, 2017 By Lisette Hilton The FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older. Rosacea treatments January 10, 2017 By John Jesitus Newer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end. Factors in rosacea pathogenesis clearer January 01, 2017 By John Jesitus Keeping abreast of findings regarding the immunological, neurological and vascular roots of rosacea helps dermatologists target treatments accordingly, experts say. Will new autoimmune drugs address cost concerns? December 27, 2016 By Erin Bastick PharmD Find out what’s in the drug pipeline for autoimmune disease. The digital skin health revolution December 21, 2016 By Bob Kronemyer Mobile app for acne opens the door for use with skin aging and other aesthetic skin conditions. Dermatology’s 2017 Game Changers December 19, 2016 By Lisette Hilton Several dermatologists go over what they're most excited about to see in 2017 in a number of different topics ranging from AD treatment to off-label technology use, to more male patients. First-ever U.S. psoriasis treatment goals December 15, 2016 By Bob Kronemyer The National Psoriasis Foundation has recently published psoriasis treatment goals, which will help physicians and patients discuss treatment options and set expectations for outcomes. December Clinical Considerations for NPs, PAs In this month's Clinical Considerations, we take a look at AD and bullying, whether or not derms are doing enough for psoriasis patients, and the potential of Epicutaneous immunotherapy. Novel immunomodulators expected to usher in new therapeutic era A number of systemic and topical treatments for atopic dermatitis are being developed that feature novel mechanisms of action targeting the inflammatory axes involved in the disease.